Jason Carroll's lab have been interested in the key, lineage-defining transcription factors in hormone-dependent cancer, including estrogen receptor (ER) positive breast cancer and prostate cancer. Recent evidence suggests that inhibition of these key transcription factors in prostate cancer can cause a transdifferentiation from adenocarcinoma to Neuroendocrine Prostate Cancer (NEPC), an aggressive, poorly understood subtype that is being enriched for due to more effective treatments. They have a hypothesis that a new set of lineage-defining transcription factors are switched on in NEPC, including a neuronal transcription factor called Ascl1, which they previously explored in a different neuronal cancer (neuroblastoma). They recently received funding from PCUK to explore the hypothesis of Ascl1 becoming a driver in NEPC. Jason will discuss their planned work and the hypothesis that forms the basis of this recently funded project.